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The Epstein-Barr virus (EBV) immediate-early protein BZLF1 (Z) is a key regulator of the EBV latent-to-
lytic switch. Z is a transcriptional activator which induces EBV early gene expression. We demonstrate here
that Z interacts with CREB-binding protein (CBP), a histone acetylase and transcriptional coactivator. This
interaction requires the amino-terminal region of CBP as well as the transactivation and leucine zipper
domains of Z. We show that CBP enhances Z-mediated transactivation of EBV early promoters, in reporter
gene assays and in the context of the endogenous genome. We also demonstrate that Z decreases CREB
transactivation function and that this inhibitory effect is reversed by overexpression of CBP. We show that Z
also interacts directly with CREB. However, mutational analysis indicates that Z inhibition of CREB activity
requires the direct interaction between Z and CBP but not the direct interaction between Z and CREB. We
propose that Z interacts with CBP to enhance viral early gene transcription. In addition, the Z-CBP interaction
may control host cellular transcription factor activity through competition for limiting amounts of cellular CBP.
Epstein-Barr virus (EBV) is a human herpesvirus that has
infected a large majority of the world’s population. EBV is
responsible for the onset of infectious mononucleosis and has
been found in association with a number of cancers, including
Burkitt’s lymphoma and nasopharyngeal carcinoma (52, 68).
EBV infects primarily two cell types: epithelial cells, where it
exists in a lytic state, and B cells, where it persists in a latent
state (33, 41, 52, 57). Periodically, the virus of a latently in-
fected B cell can undergo lytic replication. This disruption of
latency is characterized by a cascade of viral gene expression:
immediate-early gene expression, followed by early gene ex-
pression, and then late gene expression (33).
The immediate-early gene BZLF1 encodes a transcriptional
activator, Z, that plays a key role in the disruption of EBV viral
latency (8, 11, 60). Z transcriptionally activates its target genes
by binding to Z-responsive elements (ZREs) which are similar
to AP1 sites and are present in many of the EBV early gene
promoters (7, 16, 42, 51, 54), as well as in the promoters of the
two immediate-early genes, BZLF1 and BRLF1 (21, 49). Z is
also required for lytic replication of the virus and binds to the
origin of lytic replication, oriLyt (7, 17, 18, 54).
Z is a 245-amino-acid protein that contains specific domains
for transactivation, DNA binding, and protein-protein dimer-
ization (20, 36, 49). Z is a member of the bZIP family of
proteins and shares homology within the DNA-binding domain
to the c-Fos and c-Jun proteins (7, 16, 21). The Z protein has
been shown to interact with its cellular environment by asso-
ciating with a number of cellular proteins. Our laboratory has
shown that Z can interact directly with p53 and the NF-kB
subunit p65 (27, 67). It is likely that Z alters the functions of
these proteins in order to promote viral replication.
CREB-binding protein (CBP) is a transcriptional regulator
by virtue of its histone acetylase activity (5). The association of
histones and DNA becomes weakened by histone acetylation,
leading to altered nucleosomal conformation and stability (48).
This chromatin alteration may then facilitate transcription by
the transcriptional machinery (39, 63). CBP and the highly
homologous protein p300 have been shown to interact with
several cellular proteins, including p53, p65, c-Jun, c-Myb,
Ets-1, and NFAT1, as well as viral proteins such as adenovirus
E1A, simian virus 40 (SV40) T antigen, cytomegalovirus
(CMV) IE2, herpes simplex virus VP16, and human immuno-
deficiency virus type 1 Tat (4, 12–14, 23, 24, 28, 43, 55, 56, 62,
65).
Since Z is a potent transcriptional activator, it may target
histone acetylase activity to the early viral promoters, either by
interacting with CBP directly or by possessing an intrinsic hi-
stone acetylase activity. Here we demonstrate that Z and CBP
physically interact both in vivo and in vitro. We have mapped
the regions of this interaction, for both Z and CBP, and show
that Z and CBP interact in a functional manner to activate
EBV early gene expression. We have also discovered that Z
inhibits the transcriptional activation function of the transcrip-
tion factor CREB. We propose that Z may inhibit CREB
function by competing for limiting amounts of CBP.
MATERIALS AND METHODS
Cell lines. DG75, an EBV-negative Burkitt’s lymphoma cell line, was main-
tained in RPMI 1640 medium supplemented with 10% fetal calf serum. HeLa is
a cervical carcinoma cell line; D98/HE-R-1 is an EBV-positive epithelial cell line
formed by the fusion of a HeLa subclone (D98) with the EBV-positive Burkitt’s
lymphoma cell line P3HR/1. Epithelial cell lines were maintained in Dulbecco’s
modified Eagle’s medium H supplemented with 10% fetal calf serum.
Adenovirus construction and infection. The BZLF1 cDNA was cloned into a
shuttle vector (under the control of the CMV promoter) which contains a Lox P
site, the left adenovirus terminal repeat, and a packaging signal. This vector was
recombined (in a cell line expressing the phage P1 Cre protein) into the Lox P
site of an adenovirus lacking the E1 and E3 genes, as well as lacking a packaging
sequence, to create adenovirus-Z. A control vector containing the lacZ gene
(adenovirus-LacZ) was made in the same manner.
HeLa cells were plated at a cell density of 3 3 106 cells per 150-mm-diameter
plate. Cells were infected with no adenovirus (mock), adenovirus-LacZ, or ad-
enovirus-Z at a multiplicity of infection of 50. The cells were harvested 24 h
postinfection.
Plasmids. EApBS-CAT contains the early EBV BMRF1 promoter sequences
from 2331 to 11 linked to the chloramphenicol acetyltransferase (CAT) gene
(51). BHRF1-CAT contains a 1,020-bp NaeI-HincII fragment of the early
BHRF1 promoter (EBV positions 52800 to 53819) (27). GAL4-E1B-CAT (gift
of Michael Green) contains five copies of the GAL4 DNA-binding site upstream
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of the E1B minimal TATA element and the CAT gene (44). GAL4-CREB (gift
of Michael Green) contains the GAL4 DNA-binding domain fused to the CREB
cDNA in the SG424 vector (53). Zp-CRE-CAT contains three copies of the CRE
site from the Z promoter (TGACATCA) fused to the E1B minimal TATA
element and the CAT gene.
The Z expression vector contains the BZLF1 cDNA, downstream of the CMV
immediate-early promoter, in the pHD1013 vector (51). The ZE2ter expression
vector has a deletion of the Z carboxy-terminal amino acids 228 to 245, down-
stream of the SV40 immediate-early promoter, in the pKSV vector (gift of Alain
Sergeant). The Z311 expression vector contains a mutation in the DNA-binding
domain of Z in which amino acid 185 is altered (abolishing DNA binding),
downstream of the CMV immediate-early promoter, in the pHD1013 vector (25,
31). Z-CT (previously referred to as RAZDR), contains amino acids 2 to 86
deleted (gift of Joseph Pagano) (22). ZD200 contains a mutation of amino acid
200 of Z from tyrosine to glutamic acid, downstream of the CMV immediate-
early promoter, in the pHD1013 vector. The CBP expression vector contains the
CBP cDNA, downstream of the CMV immediate-early promoter (gift of Michael
Rosenfeld) (29). CBP-HAT(2) contains mutations of amino acids 1689 and 1690
of CBP from leucine-cysteine to lysine-leucine, downstream of the CMV imme-
diate-early promoter (gift of Jenny Ting). The CREB expression vector contains
the CREB gene, downstream of the Rous sarcoma virus promoter (gift of
Michael Green; from Marc Montminy). The protein kinase A (PKA) expression
vector contains the gene for the catalytic subunit of PKA, downstream of the
mouse metallothionein 1 promoter (gift of Michael Green; from Stanley Mc-
Knight).
The Z cDNA plasmid contains the BZLF1 cDNA in the pSP64 (Promega)
vector (a gift from Paul Farrell) (16). The Z cDNA was also inserted into the
pBluescript (pBS; Stratagene) vector so that it could be cut with HincII to make
a carboxy-terminal truncation of Z (referred to as ZDter). ZDLZ (from Alain
Sergeant) was cut out of the pKSV vector with EcoRI and cloned into pBS. Z-NT
contains amino acids 1 to 140 of Z. Z-CT is RAZDR in the pBS vector (22).
ZD200 contains a mutation at amino acid 200 of tyrosine to glutamic acid, in the
pSP64 vector. ZD214/218 contains mutations at amino acids 214 and 218 (both
leucine to serine), in the pSP64 vector.
pGEX-3X-Z contains the Z cDNA fused in frame to the glutathione S-
transferase (GST) gene in the pGEX-3X (Pharmacia) vector (51). CBP was
subcloned as five pieces into the pGEX vector (fragments 1 to 721, 706 to 1009,
1069 to 1459, 1459 to 1891, and 1892 to 2441) (gifts of Michael Rosenfeld) (29).
pGEX-CREB contains the CREB cDNA fused in frame to GST in the pGEX1
vector (gift of Michael Green). pGEX-3X was used as the control vector.
DNA purification. Plasmid DNA was purified through Qiagen columns as
described by the manufacturer.
DNA transfection. DNA (5 to 10 mg) was transfected into cells by electropo-
ration with a Zapper electroporation unit (Medical Electronics Shop, University
of Wisconsin) at 1,500 V as described elsewhere (61). All cells were resuspended
in RPMI 1640 medium prior to electroporation.
CAT assays. Cell extracts were prepared 48 h posttransfection and incubated
at 37°C with [14C]chloramphenicol in the presence of acetyl coenzyme A as
described elsewhere (26). The percent acetylation of chloramphenicol was quan-
titated by thin-layer chromatography followed by PhosphorImager screening
(Molecular Dynamics).
Immunoblot analysis. Immunoblot analysis was performed for the detection of
the Z, retinoblastoma (Rb), BMRF1 (early-antigen diffuse; EAD), and CREB
proteins as follows. Briefly, 10 to 100 mg of protein was loaded in each lane, and
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) was
performed. The proteins were transferred overnight onto nitrocellulose (Prot-
ran), blocked in 13 phosphate-buffered saline (PBS)–5% milk–0.1% Tween 20,
and incubated in primary antibody for 1 h at room temperature (BZ1 [1:40; from
Alan Rickinson] [66]; anti-Rb [1:400; PharMingen]; anti-EBV [EAD; 1:100;
Capricorn] anti-CREB [1:500; Santa Cruz Biotechnology]). The membrane was
washed in PBS–0.1% Tween 20, incubated in secondary antibody for 1 h at room
temperature (goat anti-mouse kappa-horseradish peroxidase [1:2,000; Southern
Biotechnology]; goat anti-rabbit conjugated to horseradish peroxidase [1:10,000;
Promega]) and washed, and the results were visualized with an ECL (enhanced
chemiluminescence) kit (Amersham) according to the manufacturer’s instruc-
tions.
Z protein expression. The Z cDNA plasmid in SP64 was linearized with EcoRI
and transcribed with SP6 polymerase, using a Riboprobe System II kit from
Promega. The resulting RNA was translated in the presence of [35S]methionine,
using the rabbit reticulocyte lysate system (Promega). The Z cDNA plasmid in
SP64 was also cut with NheI to make Z-NT. The Z cDNA in pBS was cut with
HincII and prepared as described above to yield a carboxy-terminal deletion of
Z. ZDLZ was transcribed uncut, while Z-CT was cut with SalI and prepared as
for Z. ZD200 and ZD214/218 were both linearized with EcoRI and transcribed
with SP6. Protein quantities were normalized by running aliquots of each protein
on an SDS-polyacrylamide gel, followed by autoradiography.
GST, GST-Z, GST-CREB, and GST-CBP proteins were induced, sonicated,
and centrifuged. Protein quantities were normalized by affinity purifying aliquots
of the proteins, followed by SDS-PAGE and Coomassie staining.
Immunoprecipitation. HeLa cells were infected with no adenovirus (mock),
adenovirus-LacZ, or adenovirus-Z. Cells were harvested after 24 h and resus-
pended in buffer 7 (20 mM HEPES [pH 7.7], 25 mM NaCl, 2.5 mM MgCl2, 0.1
mM EDTA, 1 mM dithiothreitol, 0.05% Nonidet P-40, protease inhibitors),
sonicated, and centrifuged. Anti-CBP antibody (Santa Cruz), anti-CREB anti-
body (Santa Cruz), or rabbit serum (Sigma) was added to 10 to 100 mg of protein
and incubated for 1 h at 4°C. The reaction mixtures were then incubated with
protein A-Sepharose beads for 1 h at 4°C. The beads were washed three times
with buffer 7 and loaded onto an SDS-polyacrylamide gel. Ten micrograms of
crude extract was loaded onto the gel for a control. Immunoblot analysis was
performed with either an anti-Z antibody or an anti-CREB antibody.
Affinity chromatography. The GST fusion proteins were incubated with glu-
tathione-agarose beads for 10 min at room temperature. The beads were washed
three times with PBS, resuspended in buffer 7 or buffer CBP (25 mM HEPES
[pH 7.3], 100 mM sodium chloride, 5 mM magnesium chloride, 100 mM EDTA,
0.2 mg of bovine serum albumin per ml, 0.1% Tween 20, protease inhibitors), and
incubated with 2.5 to 10 ml of in vitro-translated protein for 1 h at room
temperature. The beads were washed five to six times with buffer and loaded
onto an SDS-polyacrylamide gel. After electrophoresis, the gel was fixed in 50%
methanol plus 10% acetic acid, enhanced in 1 M sodium salicylate, and exposed
to X-ray film.
RESULTS
Z interacts with CBP in vivo. Since several transcriptional
activators have recently been shown to interact with CBP
and/or p300 to facilitate the opening of chromatin, we inves-
tigated whether Z, a transcriptional activator of the EBV early
genes, can physically interact with CBP. CBP was immunopre-
cipitated from extracts of HeLa cells that had been mock
infected, infected with a replication-deficient adenovirus ex-
pressing the lacZ gene (as a control), or infected with a repli-
cation-deficient adenovirus expressing the Z gene. Following
the CBP immunoprecipitation, we performed immunoblot
analysis with an anti-Z antibody (Fig. 1A). The results clearly
demonstrate that the anti-CBP antibody coimmunoprecipi-
tates Z from the adenovirus-Z-infected extract. A control an-
tibody (rabbit serum) did not coimmunoprecipitate Z. There-
fore, Z and CBP physically interact in vivo. As a negative
FIG. 1. Z and CBP associate in vivo. (A) Anti-CBP antibody and a control
antibody (Ab.) (rabbit serum) were used to coimmunoprecipitate Z from mock-,
adenovirus-LacZ-, or adenovirus-Z-infected HeLa cell extracts (100 mg) (lanes 1
to 6). Direct loads (10 mg) of each extract were used to confirm the presence of
Z (lanes 7 to 9). Western blot analysis was performed with an anti-Z antibody.
(B) Anti-CBP antibody and a control antibody (rabbit serum) were used to
coimmunoprecipitate Rb from adenovirus-LacZ- or adenovirus-Z-infected
HeLa cell extracts (100 mg) (lanes 1 to 4). Direct loads (20 mg) of each extract
were used to confirm the presence of Rb (lanes 5 and 6). Western blot analysis
was performed with an anti-Rb antibody.
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control, we attempted to coimmunoprecipitate the Rb protein
from the same extracts (Fig. 1B). Rb has been shown to inter-
act with histone deacetylase activity (5a), and therefore we
speculated that it would not interact with CBP. We did not
coimmunoprecipitate CBP and Rb, demonstrating that our
procedure does not allow for nonspecific coimmunoprecipita-
tions.
Z interacts with the first 721 amino acids of CBP. To ex-
amine which region of CBP is responsible for the CBP-Z in-
teraction, we performed affinity chromatography experiments
with five consecutive segments of CBP (as depicted in Fig. 2A)
fused to GST and in vitro-translated Z protein. The in vitro-
translated Z protein did not bind to GST alone but did ho-
modimerize with GST-Z, as expected (Fig. 2B). Z bound to the
GST-CBP protein containing the first 721 amino acids of CBP
but not to the other regions of CBP. The amino terminus of the
CBP protein has also been shown to interact with several other
transcriptional activators, including CREB, c-Jun, and p65 (4,
9, 24).
Several domains of Z are required for association with CBP.
To determine which regions of Z are necessary for the Z-CBP
association, we performed affinity chromatography experi-
ments with in vitro-translated wild-type Z and Z mutants, as
depicted in Fig. 3A, and GST-CBP(1-721). The results indi-
cated that a large portion of the Z protein is necessary for the
Z-CBP interaction. The leucine zipper of Z is required for
interaction with CBP (as well as for Z homodimerization) (Fig.
3B, lanes 5 to 8). Furthermore, a mutant form of Z that is
incapable of homodimerization (ZD214/218) is unable to as-
sociate with CBP (Fig. 3B, lanes 9 to 12), suggesting that the
Z/CBP interaction requires Z dimerization. However, the car-
boxy-terminal half of Z (Z-CT) is insufficient for the CBP
interaction (Fig. 3B, lanes 13 to 16). The amino-terminal half
(containing the transcriptional activation domain) (Z-NT) is
also required, although not in itself sufficient, for the CBP
interaction (Fig. 3B, lanes 21 to 24). In addition, a mutant form
of Z lacking the carboxy-terminal 17 amino acids cannot inter-
act efficiently with CBP (Fig. 3B, lanes 17 to 20). Finally, two
mutant forms of Z containing mutations in the DNA binding
domain, Z311 (altering residue 185 from alanine to lysine) and
Z(S186A), were still able to associate with CBP (data not
shown). The finding that both the amino- and carboxy-terminal
domains of Z are essential for interaction with CBP suggests
that a certain conformation of Z may be required for this
interaction or that Z contacts two distinct regions (within the
amino terminus) of CBP.
Z synergizes with CBP to activate the EBV early genes
BMRF1 and BHRF1. CBP enhances transcriptional activation
by acting as a histone acetylase and destabilizing nucleosome
structure. The disruption of chromatin organization is thought
FIG. 2. Z binds to the amino-terminal portion of CBP. (A) Schematic of the
CBP protein. The regions previously reported to bind various proteins are indi-
cated. Below the CBP map are the five segments of CBP that have been fused to
GST. (B) Affinity chromatography experiments were performed in which 10 ml of
in vitro-translated Z was incubated with GST alone, GST-Z, or the GST-CBP
segments (amino acids 1 to 721, 706 to 1009, 1069 to 1459, 1459 to 1891, and 1892
to 2441) bound to glutathione-agarose beads. Lane 1 shows the direct load of in
vitro-translated Z protein (10 ml).
FIG. 3. The Z-CBP association requires several regions of the Z protein. (A)
Schematics of the wild-type Z protein (Z wt) and the various Z mutants used in
this study. The transactivator (TA), dimerization (DIM), and DNA binding
domains are indicated. (B) Aliquots of 5 ml of in vitro-translated wild-type Z
protein (lanes 2 to 4), 10 ml of in vitro-translated ZDLZ (lanes 6 to 8), 5 ml of in
vitro-translated ZD214/218 (lanes 10 to 12), 5 ml of in vitro-translated Z-CT
(lanes 14 to 16), 5 ml of in vitro-translated ZDter (lanes 18 to 20), or 5 ml of in
vitro-translated Z-NT (lanes 22 to 24) were incubated with GST alone, GST-Z,
or GST-CBP(1-721). Lanes 1, 5, 9, 13, 17, and 21 contain the direct loads for each
protein (3 ml of Z, 10 ml of ZDLZ, 5 ml of ZD214/218, 5 ml of Z-CT, 5 ml of ZDter,
and 3 ml of Z-NT).
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to aid in the access of the transcriptional machinery to DNA.
Since we found that Z and CBP physically interact, we next
examined whether CBP enhanced the ability of Z to activate
EBV early gene promoters. In transient reporter gene assays,
CBP enhanced the Z-mediated activation of the EBV early
gene promoters, BMRF1 and BHRF1 (Fig. 4A). The increase
in Z-induced activation of the BMRF1 and BHRF1 promoters
in the presence of CBP was not due to an increased level of Z
protein made by the CMV-Z expression construct (Fig. 4B).
To examine whether the histone acetylase function of CBP is
required for the CBP-mediated augmentation of Z transacti-
vator function, we performed reporter gene assays with a CBP
expression plasmid that contained two point mutations within
the histone acetyltransferase (HAT) domain, abolishing HAT
activity (35a). CBP-HAT(2) was still able to increase Z trans-
activator function to some extent, although it was significantly
less active than wild-type CBP (Fig. 4A). This ability of CBP-
HAT(2) to partially activate Z function may reflect the inter-
action between CBP and P/CAF, which is another histone
acetylase (35a).
We also examined the ability of CBP to enhance the trans-
activator activity of mutant forms of Z (those which retain
transactivator activity). As shown in Fig. 4C and D, in the
absence of exogenous CBP, a mutant form of Z, ZE2ter (which
lacks amino acids 228 to 245 and did not interact efficiently
with CBP in vitro [Fig. 3]), activated the BHRF1 and BMRF1
promoters inefficiently compared to wild-type Z. However, in
the presence of exogenous CBP, ZE2ter became a much more
efficient transcriptional activator, suggesting that this mutant
has decreased, but not absent, ability to interact with CBP in
vivo. Z311, which is unable to directly bind at least some ZREs
(25), activated the BMRF1 promoter to a low level compared
to wild-type Z, and the addition of CBP enhanced activation by
Z311 only slightly. However, Z311 unexpectedly activated the
BHRF1 promoter as well as wild-type Z, and the addition of
exogenous CBP greatly enhanced activation of the promoter
by Z311. Z311 may directly bind to the BHRF1 promoter in
vivo or, alternatively, may activate BHRF1 in an indirect man-
ner, as it activates the Z promoter (20a).
CBP increases the ability of Z to disrupt viral latency. To
examine the effect of CBP on Z-mediated transactivation of
promoters from the endogenous viral genome, we transfected
either vector DNA or Z expression plasmid with either 0, 2, 4,
or 6 mg of CBP expression plasmid (Fig. 5) and then performed
immunoblot analysis with an anti-BMRF1 (EAD) antibody.
While CBP expression alone had no effect on viral reactivation,
increasing amounts of CBP cotransfected with Z led to increas-
ing amounts of EAD production. These data demonstrate that
the Z-CBP interaction is functionally relevant in vivo, in the
context of the intact viral genome, and that CBP greatly in-
creases the efficiency of Z transactivation function.
Z inhibits CREB transactivator function. CREB is a mem-
ber of the CREB/ATF family of transcriptional activators and
associates with CBP in order to activate its transcriptional
FIG. 4. CBP enhances Z-mediated activation of EBV early gene promoters.
(A) Transient reporter assays were performed in which DG75 cells were trans-
fected with 5 mg of each promoter construct (EApBS-CAT or BHRF1-CAT) and
1 mg of Z expression plasmid with or without 2 mg of CBP expression plasmid or
CBP-HAT(2) expression plasmid (for a total of 8 mg DNA). CAT assays were
performed as described in the text. The results are a combination of at least two
separate experiments. (B) Extracts (containing either vector alone, Z, or Z plus
CBP) from one of the CAT assays above were analyzed for Z protein levels.
Western blot analysis was performed with an anti-Z antibody. (C and D) Tran-
sient reporter assays were performed in which DG75 cells were transfected with
5 mg of each promoter construct (EApBS-CAT [C] or BHRF1-CAT [D]) and 1
mg of Z, Z311, or ZE2ter expression plasmid with or without 2 mg of CBP
expression plasmid (for a total of 8 mg DNA). CAT assays were performed as
described in the text. The results are a combination of two separate experiments.
FIG. 5. CBP enhances Z-mediated transactivation of BMRF1 from the en-
dogenous viral genome. D98/HE-R-1 cells were transfected with either 2 mg of
vector (vec.; lanes 1 to 4) or 2 mg of Z expression plasmid (lanes 5 to 8), along
with increasing amounts (0, 2, 4, and 6 mg) of CBP expression plasmid. Cells were
harvested 14 h posttransfection. Western blot analysis was performed with an
anti-EAD antibody.
6554 ADAMSON AND KENNEY J. VIROL.
target promoters (9, 37). The level of CBP/p300 in cells is
limiting, such that other viral proteins (including adenovirus
E1A), which interact efficiently with CBP or p300, have been
shown to inhibit cellular transactivator function by competing
for CBP or p300 (2, 3, 40, 50, 59). Therefore, we examined the
effect of Z on CREB transactivator function. As shown in Fig.
6A, Z suppressed CREB transcriptional activity in reporter
gene assays. The inhibition of CREB’s activity by Z could be at
least partially reversed by increasing cellular CBP levels (Fig.
6A).
The Z promoter contains a CRE/ATF motif (referred to as
the ZII site) which is important for activation of Z transcrip-
tion (20b) and which has been previously shown to bind CREB,
ATF1, and ATF2 (6, 45, 64). CREB (which requires phosphor-
ylation by PKA [64a] and the presence of CBP for transcrip-
tional activation function) has been reported to activate the Z
promoter through this site (reference 19, our laboratory, and
unpublished data). Therefore, we examined the effect of Z on
CREB’s ability to activate a promoter construct containing
three copies of the ZII site linked to the minimal adenovirus
E1B promoter and the CAT reporter gene. As shown in Fig.
6B, in the presence of PKA and CBP, CREB efficiently acti-
vated the construct containing the ZII motif but did not acti-
vate a control construct containing the minimal E1B promoter
alone (data not shown). Furthermore, Z inhibited the ability of
CREB to activate the ZII motif.
Z interacts directly with CREB. The finding that exogenous
CBP expression at least partially reversed the inhibitory effect
of Z on CREB function (Fig. 6A) suggests that Z and CREB
compete for limiting amounts of cellular CBP. Therefore, we
examined the efficiency of the CREB-CBP interaction in the
presence and absence of Z. Unexpectedly, the level of coim-
munoprecipitated CREB-CBP protein complexes was not de-
creased in cells infected with adenovirus-Z (Fig. 7A). Never-
theless, it is possible that Z and CREB bind to different sites in
CBP (although both bind to regions in the first 721 amino acids
of CBP) and that both Z and CREB can bind to CBP simul-
taneously.
However, coimmunoprecipitation analysis of adenovirus Z-
infected HeLa cells suggested that Z and CREB (both bZip
proteins) also interacts directly (Fig. 7B). This interaction (as
well as the Z-CBP interaction) also occurred with bacterially
FIG. 6. Z inhibits CREB activity. (A) Transient reporter assays were per-
formed in which DG75 cells were transfected with 5 mg of GAL4-E1B-CAT, 1 mg
each of SG424 (GAL4 DNA-binding domain alone) or GAL4-CREB, and 1 mg
each of control vector or Z expression plasmid with or without 1 mg of CBP
expression plasmid (8 mg of total DNA). CAT assays were performed as de-
scribed in the text. The results are a combination of two separate experiments.
(B) DG75 cells were transfected with 5 mg of Zp-CRE-CAT and 1 mg each (or
a combination) of control vector, CREB, PKA, Z, or CBP expression plasmid (9
mg in total). CAT assays were performed as described in the text. The results are
a combination of two separate experiments.
FIG. 7. Z interacts directly with CREB. (A) Anti-CBP antibody (Ab.) and a
control antibody (rabbit serum) were used to coimmunoprecipitate (Ip) CREB
from adenovirus-LacZ- or adenovirus-Z-infected HeLa cell extracts (10 mg).
Western blot analysis was performed with an anti-CREB antibody. (B) Anti-
CREB antibody was used to coimmunoprecipitate Z from mock-, adenovirus-
LacZ-, or adenovirus-Z-infected HeLa cell extracts (100 mg) (lanes 1 to 3).
Direct loads (10 mg) of each extract were used to confirm the presence of Z
(lanes 4 to 6). Western blot analysis was performed with an anti-Z antibody. The
results from the control antibody used in this experiment are presented in Fig. 1.
(C) Aliquots of 4 ml of in vitro-translated wild-type Z protein (lanes 2 to 5), 5 ml
of in vitro-translated Z-CT protein (lanes 7 to 10), or 5 ml of in vitro-translated
ZD200 protein (lanes 12 to 15) were incubated with GST alone, GST-Z, GST-
CREB, or GST-CBP(1-721). The direct loads (lanes 1, 6, and 11) contain 4 ml of
Z, 5 ml of Z-CT, or 5 ml of ZD200. (D) DG75 cells were transfected with 5 mg of
GAL4-E1B-CAT, 1 mg each of SG424 (GAL4 DNA-binding domain alone) or
GAL4-CREB, and 1 mg each of vector, Z, Z311, Z-CT, or ZD200 expression
plasmid. CAT assays were performed as described in the text. The results are a
combination of two separate experiments. Fold activation was calculated by
taking the ratio of GAL4-CREB activity to SG424 activity in the presence of each
Z construct.
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synthesized proteins (data not shown), excluding the possibility
that the Z-CREB or Z-CBP interactions require the presence
of all three proteins. To distinguish if Z inhibition of CREB
transactivator function is due to the Z-CBP or the Z-CREB
interaction, we compared the regions of Z required for each
interaction. The amino-terminal domain of Z, which is re-
quired for interaction with CBP (Fig. 3B) but not CREB (Fig.
7C, lanes 6 to 10), is essential for Z inhibition of CREB trans-
activator function (Fig. 7D). Furthermore, amino acid 200,
within the leucine zipper of Z, is required for interaction with
CREB but not CBP (Fig. 7C, lanes 11 to 15) and is not re-
quired for Z inhibition of CREB transactivator function (Fig.
7D). These results (in addition to the finding that CBP reverses
the Z inhibitory effect) suggest that the Z-CBP interaction, and
not the Z-CREB interaction, causes the inhibition of CREB
function.
DISCUSSION
CBP is a histone acetylase and functions as a coactivator for
several cellular transcriptional activators, including p53 and
p65 (24, 56). CBP is also harnessed by viral proteins, such as
adenovirus E1A and SV40 T antigen, to promote viral gene
transactivation (13, 14, 43). Since the level of CBP in each cell
is limiting, the harboring of CBP by viral proteins can inhibit
certain cellular transcription factors, including p53, MyoD, c-
Fos, and c-Myb, that require CBP for their function (3, 10, 50,
59). Inhibition of cellular differentiation by E1A is mediated
(in part) by titration of limiting amounts of CBP/p300 (34, 47).
Therefore, competition for cellular CBP/p300 may be an im-
portant mechanism by which DNA viruses regulate the host
cell environment.
Z is a critical regulatory protein of EBV which mediates the
switch from latent to lytic infection. In addition, Z functions as
the origin-binding protein of oriLyt (17, 18, 54) and thus is a
required replicative protein. Here we have demonstrated that
the EBV immediate-early Z protein engages CBP as a coacti-
vator. Z may also associate with the closely related protein,
p300, although we have not examined this interaction. Z phys-
ically associates with CBP in vivo and in vitro, as shown by
coimmunoprecipitation and affinity chromatography studies,
through the region comprising the first 721 amino acids of
CBP. This region of CBP has also been shown to bind CREB,
c-Jun, p65, and c-Myb (4, 9, 12, 24).
It appears that at least two different domains of the Z pro-
tein are required for the Z-CBP association in vitro. Previous
reports indicate that many transcriptional proteins, including
p53, p65, c-Jun, and c-Myb, interact with CBP through their
transactivation domains (4, 12, 24, 56). Consistent with this,
deletion of the Z transactivation domain (amino acids 1 to 86)
completely abrogates the Z-CBP interaction. However, the
leucine zipper domain of Z is also clearly required for the
interaction with CBP in vitro. Z homodimerization may be
required for the transactivation domain to interact with CBP.
Alternatively, deletion of the leucine zipper may alter Z con-
formation such that the Z-CBP association cannot occur.
Although our in vitro data suggest that the carboxy terminus
of Z is also required for efficient Z-CBP interaction, our in vivo
data indicate that a Z mutant (ZE2ter) missing the carboxy
terminus is coactivated by exogenous CBP even more effi-
ciently than wild-type Z. It is possible that a cellular protein
stabilizes the interaction between Z and CBP in vivo, such that
the ZE2ter mutant can interact with CBP more efficiently in
vivo. Alternatively, the low transactivation function of the
ZE2ter mutant in the absence of exogenous CBP may reflect its
relatively poor affinity for CBP, such that it is unable to com-
pete for limiting amounts of CBP in the normal host cell
environment but can function as well as wild-type Z when CBP
is supplied exogenously.
The interaction between Z and CBP serves to increase Z-
induced transactivation of lytic EBV promoters. We have dem-
onstrated here that increased levels of CBP enhance Z-medi-
ated transcriptional activation of two EBV early gene
promoters, BMRF1 and BHRF1, in reporter gene assays and
that CBP enhances Z-mediated activation of BMRF1 from the
endogenous viral genome. By physically associating with CBP,
Z presumably tethers CBP to EBV early gene promoters con-
taining Z-binding sites. CBP-mediated acetylation of histones
would then aid in transcriptional activation of EBV early pro-
moters. Interestingly, the BHRF1 promoter appears to be
more dependent on the Z-CBP interaction than the BMRF1
promoter. Therefore, the exact number and positioning of the
ZRE sites may influence the degree Z-CBP synergy. A histone
acetylase-deficient mutant of CBP partially retains the ability
to enhance Z-mediated transcription. This may be explained
by the fact that CBP interacts with another histone acetylase,
P/CAF, and that the activity of P/CAF may contribute to the
enhancement of Z function observed with CBP (35a).
In addition to the role of the Z-CBP interaction for inducing
early gene transcription, this interaction could potentially be
important for Z’s role as the oriLyt origin-binding protein.
Origin-binding proteins may function to open chromatin, al-
lowing formation of the replication complex. The interaction
between Z and CBP may thus be required for histone acety-
lation near oriLyt ZRE sites, thereby allowing access of the
replication machinery. In addition, CBP has been recently
shown to localize within promyelocytic leukemia protein
(PML)-containing nuclear bodies (38). The ability of herpes
simplex virus and CMV immediate-early proteins to localize
within and subsequently disperse PML bodies appears to be
important for lytic replication (1, 15, 30, 35, 46). Assuming that
lytic EBV replication likewise requires modulation of PML-
associated nuclear bodies, the Z-CBP interaction could poten-
tially provide a mechanism for disrupting the PML-CBP inter-
action.
Although the Z-CBP interaction is likely required for effi-
cient transactivation of EBV early promoters, it may also be
important for regulating host cell transcription factors. Our
results clearly indicate that Z inhibits CREB transactivation
function in GAL4 reporter gene assays. This inhibition is alle-
viated by the overexpression of CBP; therefore it is likely that
Z competes with CREB for CBP. These results are in contrast
with the effect of the CMV immediate-early IE2 protein, which
utilizes its interaction with CBP to enhance CREB-mediated
transactivation (55), but are in accordance with the effect of
the adenovirus E1A protein, which has been shown to decrease
CREB activity (2). The inhibition of CREB by Z requires the
amino terminus of Z, consistent with our in vitro data showing
that the CBP-Z interaction involves this region.
The interpretation that Z inhibits CREB function by com-
peting for limiting amounts of CBP may be overly simplistic, in
that the total number of CREB-CBP complexes was not de-
creased in the presence of Z (Fig. 7A). Furthermore, Z and
CREB also directly interact. Nevertheless, our mutational
analysis suggests that Z inhibition of CREB function requires
its ability to interact directly with CBP but not CREB. One
explanation for these results is that Z also interacts with p300
through the same domains required for its interaction with
CBP and that the Z-p300 interaction competitively inhibits the
CREB-p300 interaction. At this point, the functional role of
the Z-CREB interaction remains unknown, but it could poten-
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tially be important for regulating early EBV transcription
through either ZRE/AP1- or CREB-binding motifs.
CREB-binding sites have been identified in two promoters
within the EBV genome, the Z promoter (6, 45, 64) and the
LMP1 promoter (58). CREB has been shown to activate the Z
promoter through the ZII regulatory element (reference 19,
our laboratory, and unpublished data). Z inhibition of CREB
function could serve to autoregulate the Z promoter and turn
off Z expression after critical amounts of the protein are pro-
duced. In addition, we have previously shown that Z inhibits
the activity of the LMP1 promoter (32).
E1A, by interacting with CBP, decreases the activities of
other transcription factors, including p53, by competing for
limiting amounts of cellular CBP (59). Although we have spe-
cifically shown that Z inhibits CREB transactivator function,
the Z-CBP interaction could likewise inhibit the functions of
other transcription factors regulated by CBP. Interestingly, we
have previously shown that two of the transcription factors
known to interact with CBP (p53 and p65) can inhibit BZLF1
function (and vice versa) (27, 67). Interaction with CBP/p300
may prove to be a common mechanism by which viruses reg-
ulate the host cell environment.
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